|

AVZO-023 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Avenzo Therapeutics, Inc.1

Indications

  • HR+, HER2-, Advanced Breast Cancer1
  • HR+/HER2- Breast Cancer1
  • Breast Cancer1
  • Cancer1

Los Angeles, California1 trial

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.